Will routine therapeutic drug monitoring have a place in clozapine therapy?

Clinical Pharmacokinetics

Volumn 32, Issue 2, 1997, Pages 93-100

  Freeman, David J ^a,b   Oyewumi, L Kola ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CIMETIDINE; CLOZAPINE; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; PHENYTOIN; VALPROIC ACID;

AGRANULOCYTOSIS; CONFUSION; DELIRIUM; DOSE RESPONSE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; HUMAN; HYPOTENSION; MEDICAL DECISION MAKING; ORAL DRUG ADMINISTRATION; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; REVIEW; SCHIZOPHRENIA; SEIZURE; TACHYCARDIA; VERTIGO;

EID: 0031048241     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199732020-00001     Document Type: Review

References (54)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double blind comparison versus chlorpromazine. Arch Gen Psychiatry 1988; 45 (9): 789-96
2. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989; 50: 9-13
3. Fitton A, Heel RC. Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990; 40 (5): 722-47
4. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324: 746-54
5. Jann MW, Grimsley SR, Gray EC, et al. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24 (2): 161-76
6. Vincent PC. Drug induced aplastic anaemia and agranulocytosis: incidence and mechanism. Drugs 1986; 31: 52-6
7. Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 1989; 99: 5118-21
8. Sandoz (Canada) Product Monograph 1992.
9. Love DJ, Schalk DC, Morgan MC. Computerized relational database for monitoring clozapine therapy. Am J Hosp Pharm 1993; 50: 1657-62
10. Choc MG, Lehr RG, Hsuan F, et al. Multi-dose pharmacokinetics of clozapine in patients. Pharm Res 1987; 4: 402-5
11. Cheng F, Lunberg T, Bondesson U, et al. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol 1988; 34: 445-9
12. Ackenheil M. Clozapine: pharmacokinetic investigations and biochemical effects in man. Psychopharmacology 1989; 99 Suppl.: 32-7
13. Choc MG, Hsuan F, Honigfeld G, et al. Single- vs multi-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res 1990; 7: 347-51
14. Haring C, Meise U, Barnas SC, et al. Dose related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology 1989; 99 Suppl.: 38-40
15. Choc D. Sandoz, Canada document. DM-1-11/6/91
16. Pirmohamed M, Williams D, Madden S, et al. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995; 272: 984-90
17. Bertilsson L, Carillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38 (5): 471-3
18. Jerling M, Lindstrom L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of the metabolism of clozapine. Ther Drug Monit 1994; 16: 368-74
19. Watkins P. Drug metabolism by cytochromes P450 in the liver and bowel. Gastroenterol Clin North Am 1992; 21: 511-26
20. Perry PJ, Miller DD, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148: 231-5
21. Miller DD, Fleming F, Holman TL, et al. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994; 55 (9 Suppl. B): 117-21
22. Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994; 55 (9 Suppl. B): 133-6
23. Kronig MH, Munne RA, Szymanski S, et al. Plasma clozapine levels and clincal response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995; 152 (2): 179-82
24. Hasegawa M, Gutierrez-Esteinou R, Way L, et al. Relationship between clinical efficiacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993; 13 (6): 383-90
25. Oyewumi LK, Freeman DJ, Vollick D. Can low-dose clozapine pharmacokinetics predict steady-state plasma concentrations. Ther Drug Monit 1995; 17: 137-41
26. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991; 41: 369-71
27. Simpson GM, Cooper TA. Clozapine plasma levels and convulsions. Am J Psychiatry 1978; 135: 99-100
28. Funderberg LG, Vertress JE, True JE, et al. Seizure following addition of erythromycin to clozapine treatment. Am J Psychiatry 1994; 151: 1840-1
29. Piscitelli SC, Frazier JA, McKenna K, et al. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry 1994; 55 (9 Suppl. B): 94-7
30. Alvir JMJ, Jeffrey PH, Lieberman JA, et al. Clozapine-induced agranulocytosis incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-7
31. Gerson SL, Meltzer H. Mechanisms of clozapine-induced agranulocytosis. Drug Saf 1992; 7 Suppl I: 17-25
32. Gerson SL, Arce C, Meltzer HY. N-desmethyl clozapine: a metabolite that suppresses haematopoiesis. Br J Haematol 1994; 86: 555-61
33. 51Cr release assay of clozapine-induced cytotoxicity: evidence for immunogenic mechanism. J Clin Psychiatry 1994; 9 Suppl. B: 143-8
34. Hasegawa M, Cola PA, Meltzer HY. Plasma clozapine and desmethylclozapine levels in clozapine-induced agranulocytosis. Neuropsychopharmacology 1994; 11: 45-7
35. Centorrino F, Baldessarini R, Flood JG, et al. Relation of leukocyte counts during clozpine treatment to serum concentrations of clozapine and metabolites. Am J Psychiatry 1995; 152: 610-2
36. Uetrecht JP. Metabolism of clozapine by neutrophils: possible implication for clozapine-induced agranulocytosis. Drug Saf 1992; 7 Suppl. 1: 51-6
37. Liu ZC, Uetrecht JP. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to cells. J Pharmacol Exp Ther 1995; 275: 1476-83
38. Maggs JL, Williams D, Pirmohamed M, et al. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Med 1995; 275: 1463-75
39. Haring C, Barnas SC, Humpel C, et al. Dose related plasma levels of clozapine. J Clin Psychopharmacol 1989; 9: 71-2
40. Oleson O, Thomsen K, Jensen PN, et al. Clozapine serum levels and side-effects during steady-state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology 1995; 117 (3): 371-8
41. Fischer V, Vogels B, Mauer G, et al. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 1992; 260: 1355-60
42. Dahl ML, Llerena A, Bondesson U, et al. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994; 37 (1): 71-4
43. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 1994; 52: 23-5
44. Raitasauo V, Lehtovaara R, Huttunen MO. Carbamazepine and plasma levels of clozapine [letter]. Am J Psychiatry 1993; 150 (1): 169
45. Centorrino F, Baldessarini R, Kando J, et al. Serum concentrations of clozapine and and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994; 151: 123-5
46. Longo L, Salzam C. Valproic acid effects on serum concentration of clozapine and norclozapine [letter]. Am J Psychiatry 1995; 152 (4): 650
47. Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry 1994; 36 (7): 487-8
48. Szymanski S, Lieberman SA, Picou D, et al. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry 1991; 52; 21-2
49. Chung MC, Lin SK, Chang WH, et al. Determination of clozapine and desmethylclozapine in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1993; 613: 168-73
50. Volpicelli SA, Centorrino F, Puopolu PR, et al. Determination of clozapine, norclozapine and clozapine-N-oxide in serum by liquid chromatography. Clin Chem 1993; 39: 1656-9
51. Olesen O, Poulsen B. On-line fully automated determination of clozapine and desmethylclozapine in human serum by solid phase extraction on exchangeable cartridges and liquid chromatography using a methanol buffer mobile phase on unmodified silica. J Chromatogr 1993; 622: 39-46
52. Dollo G, Bun H, Bonnefont-Cornet M. Determiniation of clozapine by HPLC and drug monitoring applications. J Pharm Clin 1994; 13: 17-22
53. McCarthy PT, Hughes S, Paton C. Measurement of clozapine and norclozapine in plasma/serum by high performance liquid chromatography with ultraviolet detection. Biomed Chromatogr 1995; 9 (1): 36-41
54. Freeman DJ, Li MC, Oyewumi K. Solid phase extraction and high performance liquid chromatographic analysis of clozapine and norclozapine in human plasma. Ther Drug Monit 1996; 18: 688-92